Karen Chagin, MD

Dr. Chagin joined Context in June 2025 as Chief Medical Officer. Prior to joining Context, Dr. Chagin served as Senior Vice President of Early-Stage Development at Adaptimmune Therapeutics plc, a public biotechnology company. Prior to Adaptimmune, Dr. Chagin held positions of increasing responsibility at Tmunity Therapeutics, a private biotechnology company, from 2019 to 2023, ultimately becoming Chief Medical Officer, and the Head of Kite Philadelphia following Kite Pharma’s acquisition of Tmunity. From 2015 to 2019, Dr. Chagin served as Adaptimmune’s Vice President of Clinical Development. Prior to joining Adaptimmune in 2015, she served as a Scientific Director in Oncology Early Development at Janssen leading development activities for Phase 1 assets. Dr. Chagin began her career in the pharmaceutical industry in 2009 at GSK and served as a Safety Development leader before transitioning to clinical development.

Dr. Chagin holds a B.A from the University of Pennsylvania and an M.D. from Temple University School of Medicine. She performed her residency at Children’s Memorial Hospital in Chicago and her fellowship in pediatric hematology and oncology at The Children’s Hospital of Philadelphia.